Phase III Study of Osavampator for Depression

Positive topline data for the Phase II SAVITRI Istudy of osavampator in adult subjects with MDD were announced in April 2024.

"Oavampator has the potential to become a first-in-class treatment for MDD, a disorder that impacts more than 21 million people in the United States," said Dr. Eiry W. Roberts, Chief Medical Officer at Neurocrine Biosciences. "More than a third of those MDD sufferers endure debilitating symptoms that current treatment options cannot fully resolve.

"Major depressive disorder is a condition that has a profound effect on patients and their families and is associated with significant morbidity and mortality," said Dr. Maurizio Fava,  Chairman, Mass General Brigham Academic Medical Centers Department of Psychiatry. "The great majority of patients suffering from major depressive disorder do not achieve a sustained remission of their condition and the options for next step strategies to help them are quite limited. This trial is happening at a time when it is clear that, as a field, we need to develop new augmentation strategies to enhance the efficacy of standard antidepressants."

About Osavampator and the Phase III Registrational Program; Osavampator (formerly NBI-1065845) is a potential first-in-class, investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) in development as a potential treatment for patients with inadequate response to treatment in MDD. Neurocrine received an exclusive license to osavampator from Takeda Pharmaceutical Company Limited for all indications in all territories worldwide except Japan. The Phase III  registrational program is designed to assess the efficacy, safety and tolerability of osavampator in adult subjects with MDD. The study will enroll adults with a primary diagnosis of MDD, who have inadequate response to current antidepressant treatment